Wegovy injection pens organized in Waterbury, Vermont, US, on Monday, April 28, 2025.
Shelby Knowles | Bloomberg | Getty Pictures
Danish pharmaceutical big Novo Nordisk on Wednesday introduced plans to chop round 9,000 roles, or roughly 11.5% of its world workforce.
“Novo Nordisk immediately introduced a company-wide transformation to simplify its organisation, enhance the velocity of decision-making, and reallocate sources in direction of the corporate’s development alternatives in diabetes and weight problems,” the corporate, which produces the Wegovy weight reduction medicine, stated in an announcement,
“As a part of the transformation, Novo Nordisk intends to scale back the worldwide workforce by roughly 9,000 of the 78,400 positions within the firm, with round 5,000 reductions anticipated in Denmark.”
The corporate stated the headcount discount would incur a one-off price of 8 billion Danish kroner ($1.26 billion).
Because of the one-off prices, the corporate stated its now count on full-year working revenue development of 4% to 10%, down from the ten% to 16% outlined in its second-quarter leads to August.
This can be a creating story and shall be up to date shortly.